Form 4: Sangamo Therapeutics CFO Reports Routine RSU Vesting and Tax Withholding

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, reported a routine disposition of shares for tax withholding purposes following the vesting of restricted stock units.

Summary

• Prathyusha Duraibabu, SVP and Chief Financial Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on July 22, 2025.
• The transaction involved the disposition of 31,866 shares of common stock at a price of $0.4798 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of a restricted stock unit (RSU) grant.
• The transaction is not a discretionary trade by the Reporting Person but a required tax withholding event.
• Following this transaction, Prathyusha Duraibabu beneficially owns 746,279 shares of Sangamo Therapeutics common stock.
• The total beneficial ownership includes 57,197 shares from a January 22, 2024 RSU grant (with 178,125 shares remaining to vest quarterly through January 22, 2026).
• It also includes 15,030 shares from a February 24, 2023 RSU grant, vesting quarterly through February 24, 2026.
• Additionally, 120,000 shares from a February 25, 2025 RSU grant are included, with one-fourth vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments.
• All RSU vesting is contingent upon the Reporting Person's continuous service as defined in the 2018 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (tax withholding on RSU vesting). It provides no new operational or financial information that would significantly alter the company's outlook or investor sentiment, thus indicating a neutral impact.

Positives

• The vesting of restricted stock units indicates the continued employment and alignment of interests between the Chief Financial Officer and the company.
• The transaction is a routine tax-related event, not a discretionary sale, which suggests stability in insider holdings.

Negatives

• No negative implications are apparent from this routine tax withholding transaction.

Future Outlook

Future vesting schedules for the Chief Financial Officer's Restricted Stock Units are outlined, with shares from various grants expected to vest in successive equal quarterly installments through January 22, 2026, February 24, 2026, and extending beyond February 25, 2026, subject to continuous service.

Industry Context

This filing is a standard disclosure of an insider's equity compensation transaction and does not provide information directly related to broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity ownership and compensation, confirming routine tax-related share dispositions.
• Employees: Reinforces the structure of the company's equity incentive plan for key personnel.

Next Steps

• Continued vesting of remaining Restricted Stock Units for the Reporting Person on scheduled quarterly installments through January 22, 2026, February 24, 2026, and beyond February 25, 2026.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Beneficial Ownership, Tax Withholding